Moreover, SHMT2 has been found to be associated with a poor prognosis in hepatocellular carcinoma (Ji et al., 2019), intrahepatic cholangiocarcinoma (Ning et al., 2018), breast cancer (Bernhardt et al., 2017) and gastrointestinal tumors (Liu et al., 2019). This evidence concerns the gene SHMT2 and digestive system neoplasm.